Join our webinar on June 26th to explore the development and preclinical evaluation of Antibody-Drug Conjugates (ADCs), focusing on their components, mechanisms, and the selection of effective preclinical models for advancing targeted cancer therapies.
Date:
· Wednesday, June 26th, 2024; 2:00 pm EDT or 11:00 am PDT
Webinar Highlights:
- Understand the components and mechanisms of action of ADCs
- Learn about the historical development and evolution of ADCs
- Discover the importance of preclinical models in ADC development
- Explore the selection criteria for preclinical models
- Identify the challenges and future directions in ADC development
Meet Our Speaker:
Dr. Hua Wei earned his Ph.D. in Biochemistry from Ohio State University in 2008 and completed postdoctoral training at MD Anderson Cancer Center in 2009. Dr. Wei then held leadership roles in various biotech and biopharma companies in China, focusing on preclinical research for antibody and small molecule drugs. He is an expert in R&D of antibody drug discovery, overseeing the approval of a monoclonal antibody drug in 2022 and another drug for clinical trials. In mid-2022, he became Vice President of the Industrial Clients Department at the GenoBioTX.
For more information, please contact us:
Email: info@genobiotx.com; service.us@modelorg.com
